
Opinion|Videos|July 2, 2024
Experts Discuss Long-Term Effects and Monitoring in AD Therapy
Medical experts discuss the long-term consequences of extended use of topical corticosteroids or calcineurin inhibitors in atopic dermatitis (AD) patients and recommend appropriate monitoring strategies.
Advertisement
Episodes in this series

- What are the implications of long-term use of topical corticosteroids or calcineurin inhibitors in AD patients, and how should patients be monitored for these?
- Also discuss how to address concerns related to systemic exposure/absorption of topical corticosteroids
- What factors do you consider when deciding between topical and systemic therapies for patients needing treatment for AD?
Advertisement
Related to this article

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5

